drugset / Trial / NCT05698459

OH2 Oncolytic Viral Therapy Via Transcatheter Intraarterial Infusion in Patients with Advanced Liver Cancer

NCT05698459

Phase 1 Recruiting 12 enrolled Binhui Biopharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

An open-label dose-escalation phase I clinical study to evaluate the safety, tolerability and pharmacokinetics of OH2 injection via transcatheter Intraarterial infusion in patients with advanced hepatocellular carcinoma

Timeline

Start
2023-05-05
Primary completion
2025-08
Completion
2026-01

Drugs

EvaluationDrugModalityDoseRoute
Subject OH2 Other / unclassified Other

Indications